英文摘要 |
The famous American actress, Angelina Jolie underwent bilateral prophylactic mastectomy in 2013 because of her strong breast / ovarian cancer family history and the detection of a BRCA1 mutation. She also received prophylactic bilateral salpingo-oophrectomy (BSO) to prevent ovarian cancer in 2015. This is because the life risk of developing breast cancer and ovarian cancer in BRCA1/ 2 mutation carriers is as high as 87% and 60%. The BRCA1/ 2 genes, breast cancer susceptibility genes type 1 and 2, are located on chromosome XVII (BRCA1, 17q21) and XIII (BRCA2, 13q12-13). The normal function of BRCA1/ 2 is DNA repair and thus BRCA1/2 mutation results in tumorigenesis. A world-wide BRCA1/ BRCA2 mutation is detected in 20-25% of breast cancer patients with a family history and one third of BRCA1 mutation is associated with triple negative breast cancer. Prophylactic mastectomy at the age of 35 to 40 years would reduce 90% of breast cancer. Prophylactic BSO would reduce 80% of ovarian/ fallopian tube cancers and 50% of breast cancer. In this paper, we will review the pathophysiology of BRCA associated breast cancer and current management. |